Preserflo™ MicroShunt

Advanced Glaucoma Treatment Solution

A Revolutionary Approach to IOP Management

Understanding Glaucoma

  • Progressive optic nerve damage
  • Often associated with elevated intraocular pressure (IOP)
  • Leading cause of irreversible blindness worldwide
  • Affects over 80 million people globally
Global Impact of Glaucoma
80M+
Global Cases
2nd
Leading Cause of Blindness
Eye Anatomy Diagram

The Preserflo™ MicroShunt

  • Ultra-stable, biocompatible SIBS material
  • Dimensions: 8.5mm long, 350μm external diameter
  • Planar fins prevent rotation and migration
  • Precisely engineered internal lumen (70μm)
Device Specifications
8.5mm length 350μm external diameter Internal lumen: 70μm
Medical Device

Mechanism of Action

  • Creates controlled aqueous outflow pathway
  • Diverts fluid from anterior chamber to subconjunctival space
  • Forms a posterior filtration bleb
  • Maintains optimal IOP through precise engineering
Aqueous Flow Pathway
Anterior Chamber Subconjunctival Space Controlled Flow
Glaucoma Mechanism

Clinical Indications

  • Primary Open-Angle Glaucoma (POAG)
  • Uncontrolled IOP despite maximum medical therapy
  • Failed previous glaucoma surgeries
  • Patients intolerant to medication
Patient Consultation

Surgical Procedure

  • Outpatient procedure under local anesthesia
  • MMC application for bleb modulation
  • Precise placement in anterior chamber
  • Minimal tissue disruption
Surgical Environment

Clinical Benefits

  • Significant and sustained IOP reduction
  • Reduced dependency on medications
  • Standardized surgical technique
  • Faster recovery compared to traditional surgery
IOP Reduction Results
Baseline IOP 24.8 mmHg
6 Months Post-Op 13.7 mmHg
12 Months Post-Op 12.9 mmHg
Clinical Benefits

Preserflo™ vs. Trabeculectomy

Preserflo™ MicroShunt

  • Standardized procedure
  • Lower risk of hypotony
  • Faster visual recovery
  • Fewer post-op interventions

Trabeculectomy

  • More surgeon dependent
  • Higher risk of complications
  • Longer recovery period
  • More frequent follow-up needed

Safety Profile

  • Lower risk of hypotony compared to trabeculectomy
  • Minimal risk of device erosion
  • Reduced risk of infection
  • Manageable post-operative care
Safety Measures

Clinical Evidence

  • High success rates in clinical trials
  • Significant IOP reduction (40-50%)
  • Medication reduction in most patients
  • Sustained effectiveness over time
Success Rates at 12 Months
83.3%
Complete Success
No Medications
94.8%
Qualified Success
≤ 2 Medications
Clinical Research

Conclusion

The Preserflo™ MicroShunt represents a significant advancement in glaucoma surgery:

  • Innovative design with proven effectiveness
  • Standardized surgical technique
  • Excellent safety profile
  • Potential to become the new standard of care